sarcosine has been researched along with Dementia Praecox in 40 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
| Excerpt | Relevance | Reference |
|---|---|---|
| "Modulation of glutamatergic neurotransmission in schizophrenia by sarcosine leads to a reduction in primary negative symptoms, while its metabolic profile is safe." | 9.41 | Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study). ( Jerczyńska, H; Kaczmarek, B; Kotlicka-Antczak, M; Strzelecki, D; Wysokiński, A, 2021) |
| "Sarcosine, glycine transporter inhibitor, increases glycine levels around NMDA receptor, improving primary negative symptoms of schizophrenia." | 9.27 | Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). ( Strzelecki, D; Urban-Kowalczyk, M; Wysokiński, A, 2018) |
| "Currently, we observe a huge number of publications describing the role of glycine transporter (GlyT1) inhibitors in schizophrenia treatment." | 9.22 | Glycine transporters in schizophrenia. A new hope or informational noise? ( Pawlak, J; Zakowicz, P, 2022) |
| "This study was undertaken with the purpose to determine if there are changes in metabolic parameters during 6-month add-on treatment with sarcosine in patients with schizophrenia." | 9.20 | No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. ( Kałużyńska, O; Strzelecki, D; Szyburska, J; Wlazło, A; Wysokiński, A, 2015) |
| "Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia." | 9.14 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. ( Chang, YC; Huang, YJ; Lane, HY; Liao, CH; Lin, CH; Tsai, GE, 2010) |
| "Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily." | 9.13 | Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. ( Chang, YC; Huang, CL; Lane, HY; Liau, CH; Liu, YC; Perng, CH; Tsai, GE, 2008) |
| "Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics." | 9.12 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. ( Chang, YC; Chen, PW; Huang, CL; Lane, HY; Lin, PY; Liu, YC; Tsai, G; Wu, PL, 2006) |
| "This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia." | 9.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| "Sarcosine (N-methylglycine), a type 1 glycine transporter inhibitor (GlyT1), has shown therapeutic potential for treating schizophrenia; however, studies have reported conflicting results." | 9.05 | Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. ( Chang, CH; Chen, SJ; Lane, HY; Lin, CH; Liu, CY, 2020) |
| "The present findings continue to support the use of N-methyl-D-aspartate/glycine site agonists as potential new treatments for persistent negative symptoms of schizophrenia." | 8.83 | Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. ( Javitt, DC, 2006) |
| "By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice." | 7.91 | The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. ( Deng, D; Ju, J; Wang, Z; Yan, R; Yao, L; Zhou, Q, 2019) |
| "Sarcosine, which is freely sold as a dietary supplement, has pharmacological activity to boost functioning of the glutamatergic N-methyl-d-aspartate receptor (NMDAR) and hence it is a biologically rational treatment for schizophrenia." | 7.91 | A possible role for sarcosine in the management of schizophrenia. ( Curtis, D, 2019) |
| "Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliorate negative and cognitive symptoms of schizophrenia, including sarcosine, a glycine transporter-1 inhibitor." | 7.91 | Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. ( Hung, WL; Lai, WS; Lin, BX; Lu, LY; Luo, DZ; Min, MY; Pei, JC; Shih, MH; Studer, V; Tai, HC, 2019) |
| "Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia." | 7.81 | Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. ( Amiaz, R; Javitt, D; Kent, I; Rubinstein, K; Sela, BA; Weiser, M, 2015) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 7.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| "Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone." | 6.71 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. ( Chong, MY; Lane, HY; Lange, N; Tsai, G; Yang, P, 2004) |
| "Schizophrenia is a neurological disorder that alters the behavior and affects the quality of life of a patient." | 5.91 | Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia. ( Akhtar, A; Kuhad, A; Kumar, A; Sah, SP, 2023) |
| "Modulation of glutamatergic neurotransmission in schizophrenia by sarcosine leads to a reduction in primary negative symptoms, while its metabolic profile is safe." | 5.41 | Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study). ( Jerczyńska, H; Kaczmarek, B; Kotlicka-Antczak, M; Strzelecki, D; Wysokiński, A, 2021) |
| "Augmentation of sarcosine, a natural inhibitor of the glycine transporter type I, normalizes glutamatergic neurotransmission, having beneficial impact on primary negative symptoms in schizophrenia and may also influence immune system and interleukin 6 (IL-6) levels." | 5.27 | Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). ( Strzelecki, D; Urban-Kowalczyk, M; Wysokiński, A, 2018) |
| "Sarcosine, glycine transporter inhibitor, increases glycine levels around NMDA receptor, improving primary negative symptoms of schizophrenia." | 5.27 | Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). ( Strzelecki, D; Urban-Kowalczyk, M; Wysokiński, A, 2018) |
| "Currently, we observe a huge number of publications describing the role of glycine transporter (GlyT1) inhibitors in schizophrenia treatment." | 5.22 | Glycine transporters in schizophrenia. A new hope or informational noise? ( Pawlak, J; Zakowicz, P, 2022) |
| "Finding a relationship between schizophrenia symptoms severity and initial level of BDNF and its changes during augmentation of antipsychotic treatment with sarcosine." | 5.22 | BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). ( Kałużyńska, O; Strzelecki, D; Wysokiński, A, 2016) |
| "Find changes in matrix metallopeptidase-9 (MMP-9) levels during augmentation of antipsychotic treatment with sarcosine and a relationship between schizophrenia symptoms severity and initial level of MMP-9." | 5.22 | MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study). ( Kałużyńska, O; Strzelecki, D; Szyburska, J; Wysokiński, A, 2016) |
| "This study was undertaken with the purpose to determine if there are changes in metabolic parameters during 6-month add-on treatment with sarcosine in patients with schizophrenia." | 5.20 | No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. ( Kałużyńska, O; Strzelecki, D; Szyburska, J; Wlazło, A; Wysokiński, A, 2015) |
| "Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia." | 5.14 | A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. ( Chang, YC; Huang, YJ; Lane, HY; Liao, CH; Lin, CH; Tsai, GE, 2010) |
| "Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily." | 5.13 | Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. ( Chang, YC; Huang, CL; Lane, HY; Liau, CH; Liu, YC; Perng, CH; Tsai, GE, 2008) |
| "Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics." | 5.12 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. ( Chang, YC; Chen, PW; Huang, CL; Lane, HY; Lin, PY; Liu, YC; Tsai, G; Wu, PL, 2006) |
| "This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia." | 5.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| "Sarcosine (N-methylglycine), a type 1 glycine transporter inhibitor (GlyT1), has shown therapeutic potential for treating schizophrenia; however, studies have reported conflicting results." | 5.05 | Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. ( Chang, CH; Chen, SJ; Lane, HY; Lin, CH; Liu, CY, 2020) |
| "Taking into consideration the number of trials and sample size in subgroup analyses, D-serine, NAC and sarcosine as adjuncts to non-clozapine antipsychotics have therapeutic benefit in the treatment of negative and total symptoms of chronic schizophrenia." | 4.87 | Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. ( Singh, SP; Singh, V, 2011) |
| "The present findings continue to support the use of N-methyl-D-aspartate/glycine site agonists as potential new treatments for persistent negative symptoms of schizophrenia." | 4.83 | Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. ( Javitt, DC, 2006) |
| "Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliorate negative and cognitive symptoms of schizophrenia, including sarcosine, a glycine transporter-1 inhibitor." | 3.91 | Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. ( Hung, WL; Lai, WS; Lin, BX; Lu, LY; Luo, DZ; Min, MY; Pei, JC; Shih, MH; Studer, V; Tai, HC, 2019) |
| "Sarcosine, which is freely sold as a dietary supplement, has pharmacological activity to boost functioning of the glutamatergic N-methyl-d-aspartate receptor (NMDAR) and hence it is a biologically rational treatment for schizophrenia." | 3.91 | A possible role for sarcosine in the management of schizophrenia. ( Curtis, D, 2019) |
| "By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice." | 3.91 | The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. ( Deng, D; Ju, J; Wang, Z; Yan, R; Yao, L; Zhou, Q, 2019) |
| "Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia." | 3.81 | Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. ( Amiaz, R; Javitt, D; Kent, I; Rubinstein, K; Sela, BA; Weiser, M, 2015) |
| " The product of its enzymatic reaction-sarcosine has antipsychotic effect in patients with schizophrenia." | 3.78 | Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments. ( Chen, CJ; Chen, YM; Fan, A; Hong, CJ; Hsu, CL; Tsai, TH; Wang, HA; Yang, CP, 2012) |
| "Sarcosine is an amino acid involved in one-carbon metabolism and a promising therapy for schizophrenia because it enhances NMDA receptor (NMDAR) function by inhibiting glycine uptake." | 3.75 | The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. ( Hyrc, K; Thio, LL; Zhang, HX, 2009) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 3.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| "Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone." | 2.71 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. ( Chong, MY; Lane, HY; Lange, N; Tsai, G; Yang, P, 2004) |
| "Schizophrenia is a neurological disorder that alters the behavior and affects the quality of life of a patient." | 1.91 | Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia. ( Akhtar, A; Kuhad, A; Kumar, A; Sah, SP, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (30.00) | 29.6817 |
| 2010's | 21 (52.50) | 24.3611 |
| 2020's | 7 (17.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zakowicz, P | 1 |
| Pawlak, J | 1 |
| Kumar, A | 1 |
| Akhtar, A | 1 |
| Kuhad, A | 1 |
| Sah, SP | 1 |
| Yao, L | 1 |
| Wang, Z | 1 |
| Deng, D | 1 |
| Yan, R | 1 |
| Ju, J | 1 |
| Zhou, Q | 1 |
| Curtis, D | 2 |
| Fone, KCF | 1 |
| Watson, DJG | 1 |
| Billiras, RI | 1 |
| Sicard, DI | 1 |
| Dekeyne, A | 1 |
| Rivet, JM | 1 |
| Gobert, A | 1 |
| Millan, MJ | 1 |
| Chang, CH | 1 |
| Lin, CH | 2 |
| Liu, CY | 1 |
| Chen, SJ | 1 |
| Lane, HY | 7 |
| Brennan, D | 1 |
| Strzelecki, D | 9 |
| Kotlicka-Antczak, M | 4 |
| Kaczmarek, B | 1 |
| Jerczyńska, H | 1 |
| Wysokiński, A | 6 |
| Urban-Kowalczyk, M | 2 |
| Pei, JC | 1 |
| Hung, WL | 1 |
| Lin, BX | 1 |
| Shih, MH | 1 |
| Lu, LY | 1 |
| Luo, DZ | 1 |
| Tai, HC | 1 |
| Studer, V | 1 |
| Min, MY | 1 |
| Lai, WS | 1 |
| Kawaura, K | 1 |
| Koike, H | 1 |
| Kinoshita, K | 1 |
| Kambe, D | 1 |
| Kaku, A | 1 |
| Karasawa, J | 1 |
| Chaki, S | 1 |
| Hikichi, H | 1 |
| Harsing, LG | 1 |
| Timar, J | 1 |
| Szabo, G | 1 |
| Udvari, S | 1 |
| Nagy, KM | 1 |
| Marko, B | 1 |
| Zsilla, G | 1 |
| Czompa, A | 1 |
| Tapolcsanyi, P | 1 |
| Kocsis, A | 1 |
| Matyus, P | 1 |
| Amiaz, R | 1 |
| Kent, I | 1 |
| Rubinstein, K | 1 |
| Sela, BA | 1 |
| Javitt, D | 1 |
| Weiser, M | 1 |
| Podgórski, M | 3 |
| Kałużyńska, O | 6 |
| Gawlik-Kotelnicka, O | 2 |
| Stefańczyk, L | 3 |
| Gmitrowicz, A | 3 |
| Grzelak, P | 3 |
| Szyburska, J | 2 |
| Wlazło, A | 1 |
| Lin, CY | 1 |
| Liang, SY | 1 |
| Chang, YC | 5 |
| Ting, SY | 1 |
| Kao, CL | 1 |
| Wu, YH | 1 |
| Tsai, GE | 4 |
| Labrie, V | 1 |
| Lipina, T | 1 |
| Roder, JC | 1 |
| Zhang, HX | 1 |
| Hyrc, K | 1 |
| Thio, LL | 1 |
| Huang, YJ | 1 |
| Liao, CH | 1 |
| Yang, SY | 1 |
| Hong, CJ | 2 |
| Huang, YH | 1 |
| Tsai, SJ | 1 |
| Nakato, K | 1 |
| Harada, K | 1 |
| Tobe, T | 1 |
| Yamaji, T | 1 |
| Takakura, S | 1 |
| Hashimoto, K | 1 |
| Singh, SP | 1 |
| Singh, V | 1 |
| Yang, CP | 1 |
| Wang, HA | 1 |
| Tsai, TH | 1 |
| Fan, A | 1 |
| Hsu, CL | 1 |
| Chen, CJ | 1 |
| Chen, YM | 1 |
| Tsai, G | 2 |
| Yang, P | 1 |
| Chong, MY | 1 |
| Lange, N | 1 |
| Javitt, DC | 2 |
| Hashim, A | 1 |
| Sershen, H | 1 |
| Liu, YC | 3 |
| Chiu, CC | 1 |
| Lechner, SM | 1 |
| Lindsley, CW | 2 |
| Shipe, WD | 1 |
| Wolkenberg, SE | 2 |
| Theberge, CR | 1 |
| Williams, DL | 1 |
| Sur, C | 1 |
| Kinney, GG | 2 |
| Huang, CL | 2 |
| Wu, PL | 1 |
| Lin, PY | 1 |
| Chen, PW | 1 |
| Liau, CH | 1 |
| Perng, CH | 1 |
| Shim, SS | 1 |
| Hammonds, MD | 1 |
| Kee, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine[NCT00491569] | Phase 2 | 60 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia[NCT00328276] | Phase 2 | 20 participants | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
9 reviews available for sarcosine and Dementia Praecox
| Article | Year |
|---|---|
Glycine transporters in schizophrenia. A new hope or informational noise?
Topics: Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Receptors, N-Methyl-D-Aspartate; Sarcos | 2022 |
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
Topics: Antipsychotic Agents; Cognition; Drug Therapy, Combination; Glycine Plasma Membrane Transport Protei | 2020 |
[Stimulating glutamatergic neurons as a potential novel therapeutic avenue for schizophrenia].
Topics: Animals; Drug Design; Glutamates; Glycine; Humans; Neurons; Receptors, N-Methyl-D-Aspartate; Sarcosi | 2010 |
Glycine transporter-1: a new potential therapeutic target for schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials, Phase II as Topic; Glycine; Glycine Plasma Membrane | 2011 |
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Middle Aged; Ran | 2011 |
Glutamate-based therapeutic approaches: inhibitors of glycine transport.
Topics: Animals; Benzamides; Central Nervous System; Clinical Trials as Topic; Dopamine; Drug Evaluation, Pr | 2006 |
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Topics: Antimetabolites; Antipsychotic Agents; Clozapine; Cycloserine; Drug Therapy, Combination; Glutamic A | 2006 |
Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Benzamides; Benzimidazoles; Brain; Glycine; Gl | 2006 |
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Topics: Acetamides; Alanine; Antipsychotic Agents; Clozapine; Cognition; Cycloserine; Dopamine Agents; Drug | 2008 |
15 trials available for sarcosine and Dementia Praecox
| Article | Year |
|---|---|
Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study).
Topics: Antipsychotic Agents; DEAE-Dextran; Double-Blind Method; Drug Therapy, Combination; Humans; Neuropep | 2021 |
Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Body Composition; Double-Blind Method; Drug | 2018 |
Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study).
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combina | 2018 |
Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Double-Blind Method; Fema | 2015 |
No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Composition; Double-Blind Method; D | 2015 |
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Neuroglia; Neurons; Prefrontal Cortex; Proton Mag | 2015 |
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Dietary Supplements; Double-Blind Method; Female; Frontal | 2015 |
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzoates; Chronic Disease; Cognition; D-Amino- | 2017 |
BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Double-Blind Method; Female; Humans; | 2016 |
MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Enzyme-L | 2016 |
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug | 2010 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2006 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2008 |
16 other studies available for sarcosine and Dementia Praecox
| Article | Year |
|---|---|
Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia.
Topics: Animals; Glycine Plasma Membrane Transport Proteins; Ketamine; Neuroinflammatory Diseases; Quality o | 2023 |
The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model.
Topics: Animals; Cycloserine; Disease Models, Animal; Frontal Lobe; Glycine Plasma Membrane Transport Protei | 2019 |
A possible role for sarcosine in the management of schizophrenia.
Topics: Antipsychotic Agents; Dietary Supplements; Humans; Receptors, N-Methyl-D-Aspartate; Sarcosine; Schiz | 2019 |
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
Topics: Amino Acids; Animals; Autism Spectrum Disorder; Cognition; Cognition Disorders; Cycloserine; Dose-Re | 2020 |
Author's reply.
Topics: Diagnostic Tests, Routine; Humans; Sarcosine; Schizophrenia | 2020 |
Sarcosine in the management of schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Humans; Sarcosine; Schizophrenia | 2020 |
Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
Topics: Animals; Behavioral Symptoms; Brain Diseases; Disease Models, Animal; Dizocilpine Maleate; Excitator | 2019 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine | 2015 |
Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.
Topics: Animals; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Design; Glycine Plasma Membra | 2015 |
Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Pro | 2015 |
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Carrier Proteins; Clozapine; Disease Models, Animal; Glycine; Male; Mice; | 2008 |
The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.
Topics: Animals; Antipsychotic Agents; Calcium Signaling; Cell Death; Cells, Cultured; Electrophysiological | 2009 |
The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Disease Models, Animal; Glycine Plasma Membrane Tran | 2010 |
Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments.
Topics: Animals; Antipsychotic Agents; Clozapine; Crosses, Genetic; Disease Models, Animal; Gene Expression | 2012 |
Modulation of striatal dopamine release by glycine transport inhibitors.
Topics: Amino Acid Transport Systems, Neutral; Animals; Biphenyl Compounds; Corpus Striatum; Dopamine; Excit | 2005 |
Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
Topics: Animals; Antipsychotic Agents; Glycine Plasma Membrane Transport Proteins; Humans; Molecular Structu | 2006 |